Our results show that the transcription factor RFX7 acts as a tumor suppressor in mouse models of B cell lymphoma. RFX7 limits the activity of MYC, a key regulator of B cell activation and lymphomagenesis.
We also demonstrate that alterations of RFX7 found in lymphomas can substantially affect its transcriptional activity and patient prognosis. Fischer, B.
A., Chelbi, S. T.
& Guarda, G. Regulatory factor X 7 and its potential link to lymphoid cancers.
Trends Cancer 6 , 6–9 (2020). A review summarizing the associations between RFX7 and hematopoietic cancers.
Grande, B. M.
et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.
Blood 133 , 1313–1324 (2019). This paper contains information about RFX7 mutations in Burkitt lymphoma.
Mosquera Orgueira, A. et al.
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes. PLoS One 16 , e0248886 (2021).
This article describes RFX7 mutations in different lymphoid malignancies. Castro, W.
et al. The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity.
Nature Immunology published a clinical update in Infectious Disease on 02 Jun 2026.
The item focuses on RFX7 is a tumor suppressor that restricts MYC function and B cell activation.
Review the original article for the full source wording and details.